AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38558106 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro activated and patient-derived T cells with a bystander phenotype
Number of subjects: 0
Study 38558248 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 121
Study 38558248 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICI)
Number of subjects: 121
Study 38558247 — intervention group
Group type: EXPERIMENTAL
Intervention: Early palliative care (EPC)
Number of subjects: 146
Study 38558247 — intervention group
Group type: COMPARATOR
Intervention: Standard oncological care (SOC)
Number of subjects: 146
Study 38558265 — intervention group
Group type: EXPERIMENTAL
Intervention: Le Fort I osteotomy (LFIO)
Number of subjects: 35
Study 38558265 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal split ramus osteotomy (SSRO)
Number of subjects: 35
Study 38558269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (CL1) with ADIPO-IR = 4.9 ± 2.4 and WC = 96 ± 7 cm
Number of subjects: 192
Study 38558269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (CL2) with ADIPO-IR = 6.5 ± 2.5 and WC = 114 ± 7 cm
Number of subjects: 192
Study 38558269 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3 (CL3) with ADIPO-IR = 15.0 ± 4.7 and WC = 107 ± 8 cm
Number of subjects: 192
Study 38558321 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated ePRO exercise module intervention
Number of subjects: 180
Study 38558387 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 40
Study 38558387 — intervention group
Group type: COMPARATOR
Intervention: Designed physical therapy program (Control)
Number of subjects: 40
Study 38558411 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-food blended smoothie as exclusive enteral nutrition (EEN)
Number of subjects: 10
Study 38558478 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of CGRP in individuals with rosacea
Number of subjects: 123
Study 38558478 — intervention group
Group type: COMPARATOR
Intervention: Plasma levels of CGRP in healthy controls
Number of subjects: 123
Study 38558761 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert Bladder Cancer Monitor
Number of subjects: 240
Study 38558761 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder EpiCheck
Number of subjects: 240
Study 38558761 — intervention group
Group type: COMPARATOR
Intervention: Frequent cystoscopy
Number of subjects: 240
Study 38558767 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoendoscopic inguinal lymphadenectomy (VEILND)
Number of subjects: 14
Study 38558767 — intervention group
Group type: COMPARATOR
Intervention: Open inguinal lymphadenectomy (OILND)
Number of subjects: 14
Study 38558910 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate continuous training (MCT) at 60-70% of peak heart rate (HR)
Number of subjects: 231
Study 38558910 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIIT) at 90-95% peak HR
Number of subjects: 231
Study 38558910 — intervention group
Group type: COMPARATOR
Intervention: Recommendation of regular exercise (RRE) according to guidelines
Number of subjects: 231
Study 38558946 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Follow-Up (TFU)
Number of subjects: 0
Study 38558955 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-Face (F2F) Creative Movement Intervention
Number of subjects: 15
Study 38558955 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth (TH) Creative Movement Intervention
Number of subjects: 15
Study 38559210 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (home-based, individually tailored, moderate intensity, progressive walking and resistance training)
Number of subjects: 19
Study 38559210 — intervention group
Group type: COMPARATOR
Intervention: Active control (nutrition education)
Number of subjects: 19
Study 38559225 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner-assisted intervention (n=115)
Number of subjects: 231
Study 38559225 — intervention group
Group type: COMPARATOR
Intervention: Participant-only intervention (n=116)
Number of subjects: 231
Study 38559259 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative mood
Number of subjects: 449
Study 38559259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood management and self-efficacy strategies
Number of subjects: 449
Study 38559284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of umbilical cord lining stem cells (ULSCs)
Number of subjects: 18
Study 38559338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low-temperature cryoablation (ULTC)
Number of subjects: 18
Study 38559493 — intervention group
Group type: EXPERIMENTAL
Intervention: Food allergies
Number of subjects: 1680
Study 38559746 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0
Study 38559746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38559796 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cDMARD plus anti-TNF therapy
Number of subjects: 207
Study 38559796 — intervention group
Group type: COMPARATOR
Intervention: Multiple cDMARDs
Number of subjects: 207
Study 38559896 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Based Treatment (FBT)
Number of subjects: 20
Study 38559896 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups for children who survived pediatric ALL
Number of subjects: 20
Study 38559896 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial of FBT
Number of subjects: 20
Study 38560191 — intervention group
Group type: EXPERIMENTAL
Intervention: Structural abnormalities on chest CT (Emphysema, BE, TDL)
Number of subjects: 237
Study 38560191 — intervention group
Group type: EXPERIMENTAL
Intervention: Emphysema
Number of subjects: 237
Study 38560191 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchiectasis (BE)
Number of subjects: 237
Study 38560191 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree-in-bud (TDL)
Number of subjects: 237
Study 38560406 — intervention group
Group type: EXPERIMENTAL
Intervention: True PC-TEAS
Number of subjects: 188
Study 38560406 — intervention group
Group type: COMPARATOR
Intervention: Sham PC-TEAS
Number of subjects: 188
Study 38560407 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a (sc IFN β-1a) 44 μg once weekly (qw)
Number of subjects: 494
Study 38560416 — intervention group
Group type: EXPERIMENTAL
Intervention: suboptimal peak inspiratory flow (sPIF) (<60 L/min)
Number of subjects: 0
Study 38560416 — intervention group
Group type: COMPARATOR
Intervention: optimal peak inspiratory flow (oPIF) (≥60 L/min)
Number of subjects: 0
Study 38560556 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary atheroma burden (AB), percent diameter stenosis (PDS), tapering reference diameter Z score (RDZ)
Number of subjects: 51
Study 38560604 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 40
Study 38560604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 38560639 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent polymer zotarolimus-eluting stent with 12 months DAPT for troponin-positive patients
Number of subjects: 1488
Study 38560639 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent polymer zotarolimus-eluting stent with 1 month DAPT for troponin-negative patients
Number of subjects: 1488
Study 38560639 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free amphilimus-eluting stent with 12 months DAPT for troponin-positive patients
Number of subjects: 1488
Study 38560639 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-free amphilimus-eluting stent with 1 month DAPT for troponin-negative patients
Number of subjects: 1488
Study 38560639 — intervention group
Group type: EXPERIMENTAL
Intervention: HBR patients
Number of subjects: 1488
Study 38560639 — intervention group
Group type: COMPARATOR
Intervention: Non-HBR patients
Number of subjects: 1488
Study 38560901 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for SMM or worse
Number of subjects: 1043
Study 38560901 — intervention group
Group type: COMPARATOR
Intervention: Mayo Clinic risk stratification model
Number of subjects: 1043
Study 38560960 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amisulpride (100-300 mg/day)
Number of subjects: 60
Study 38560960 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine-fluoxetine combination (OFC) (5/10 mg + 20 mg)
Number of subjects: 60
Study 38561010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemoradiotherapy
Number of subjects: 804
Study 38561010 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemoradiotherapy
Number of subjects: 804
Study 38561341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal delivery of autologous culture-expanded adipose tissue-derived mesenchymal stem cells (AD-MSC)
Number of subjects: 10
Study 38561497 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dengue virus 3 (DENV-3) challenge
Number of subjects: 9
Study 38561577 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 762
Study 38561578 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year supervised exercise program
Number of subjects: 372
Study 38561578 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor (AI) therapy withdrawal
Number of subjects: 372
Study 38561578 — intervention group
Group type: COMPARATOR
Intervention: No AI withdrawal
Number of subjects: 372
Study 38561682 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium Chain Triglyceride-supplemented Ketogenic Diet (MCT-KD)
Number of subjects: 16
Study 38561682 — intervention group
Group type: COMPARATOR
Intervention: Standard Diet (SD)
Number of subjects: 16
Study 38561708 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 week physical exercise intervention (PEI) consisting of resistance and endurance exercises
Number of subjects: 112
Study 38561708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEI)
Number of subjects: 112
Study 38561727 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care volunteer services
Number of subjects: 5
Study 38561773 — intervention group
Group type: EXPERIMENTAL
Intervention: Short foot exercise in addition to hip and knee exercises
Number of subjects: 28
Study 38561773 — intervention group
Group type: COMPARATOR
Intervention: Hip and knee exercises only (Control)
Number of subjects: 28
Study 38561817 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mobilization at 6 hours after surgery
Number of subjects: 32
Study 38561817 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mobilization at 24 hours after surgery
Number of subjects: 32
Study 38561817 — intervention group
Group type: COMPARATOR
Intervention: Comparison of OI incidence after UKA vs TKA
Number of subjects: 32
Study 38561815 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month all-oral short-course regimen containing bedaquiline (BDQ)
Number of subjects: 212
Study 38561815 — intervention group
Group type: COMPARATOR
Intervention: 9-month all-oral short-course regimen without bedaquiline (BDQ)
Number of subjects: 212
Study 38561821 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait training + tSCS (Stim group)
Number of subjects: 8
Study 38561821 — intervention group
Group type: COMPARATOR
Intervention: Gait training alone (Control group)
Number of subjects: 8
Study 38562251 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab
Number of subjects: 162
Study 38562678 — intervention group
Group type: EXPERIMENTAL
Intervention: Interruptive Clinical Decision Support (CDS)
Number of subjects: 561
Study 38562678 — intervention group
Group type: COMPARATOR
Intervention: Non-Interruptive Clinical Decision Support (CDS)
Number of subjects: 561
Study 38562783 — intervention group
Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg once/day
Number of subjects: 19
Study 38562783 — intervention group
Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg twice/day
Number of subjects: 19
Study 38562783 — intervention group
Group type: EXPERIMENTAL
Intervention: Posiphen 60 mg three times/day
Number of subjects: 19
Study 38562783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 38562810 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring reasons for quitting and strategies to help in quit efforts.
Number of subjects: 11
Study 38562810 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring barriers to quitting.
Number of subjects: 11
Study 38562810 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews exploring quit strategies.
Number of subjects: 11
Study 38562824 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC-HIV (male-targeted HIV-specific decision support app)
Number of subjects: 13894
Study 38562824 — intervention group
Group type: COMPARATOR
Intervention: No EPIC-HIV (control group)
Number of subjects: 13894
Study 38562824 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIC-HIV 2
Number of subjects: 13894
Study 38562824 — intervention group
Group type: COMPARATOR
Intervention: EPIC-HIV vs No EPIC-HIV
Number of subjects: 13894
Study 38562833 — intervention group
Group type: EXPERIMENTAL
Intervention: MPER-peptide liposome (500 mcg or 2000 mcg)
Number of subjects: 24
Study 38562833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 38562873 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional financial incentives for home-based HIV counseling and testing (HBHCT) and linkage to care (R50 food voucher)
Number of subjects: 33878
Study 38562873 — intervention group
Group type: COMPARATOR
Intervention: No financial incentives for home-based HIV counseling and testing (HBHCT) and linkage to care
Number of subjects: 33878
Study 38562875 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS), administered twice daily during ICU stay.
Number of subjects: 0
Study 38562875 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation, administered twice daily during ICU stay.
Number of subjects: 0
Study 38563058 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab treatment in phase-3 trials (PRIME/NCT04183335 and PRIME2/NCT04202679)
Number of subjects: 311
Study 38563246 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment for NTM-PD
Number of subjects: 411
Study 38563386 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprocedural γ-glutamyl transferase (GGT) levels
Number of subjects: 1800
Study 38563386 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher GGT levels (based on sex-related thresholds)
Number of subjects: 1800
Study 38563683 — intervention group
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Number of subjects: 0
Study 38563683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38563697 — intervention group
Group type: EXPERIMENTAL
Intervention: New compressive garment
Number of subjects: 0
Study 38563697 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38563751 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole alone
Number of subjects: 0
Study 38563751 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole in combination with mebendazole
Number of subjects: 0
Study 38563751 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole in combination with pyrantel
Number of subjects: 0
Study 38563751 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38563805 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative Care Social Work Intervention
Number of subjects: 0
Study 38563835 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage ligation plus pulmonary vein isolation
Number of subjects: 610
Study 38563835 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein isolation alone
Number of subjects: 610
Study 38563872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tau positron emission tomography (PET)
Number of subjects: 0
Study 38563872 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodistribution study
Number of subjects: 0
Study 38563881 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT before prednisolone treatment
Number of subjects: 101
Study 38563881 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT after 8 weeks of prednisolone treatment
Number of subjects: 101
Study 38563881 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT after short-term prednisolone discontinuation at week 10
Number of subjects: 101
Study 38564122 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid CDT
Number of subjects: 21
Study 38564122 — intervention group
Group type: COMPARATOR
Intervention: CDMT
Number of subjects: 21
Study 38564167 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-Centered Empowerment Model (FCEM) intervention
Number of subjects: 70
Study 38564167 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation (CR) control group
Number of subjects: 70
Study 38564220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (≤1500 IU and ≥10 days)
Number of subjects: 603
Study 38564220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (>1500 IU and <10 days)
Number of subjects: 603
Study 38564220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4 (>1500 IU and ≥10 days)
Number of subjects: 603
Study 38564220 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (≤1500 IU and <10 days)
Number of subjects: 603
Study 38564221 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated texting program for 30 days postdischarge
Number of subjects: 4736
Study 38564221 — intervention group
Group type: COMPARATOR
Intervention: Standard transitional care management telephone call
Number of subjects: 4736
Study 38564243 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management (money for nondrinking days) for at least 30 days followed by a brief motivational interview.
Number of subjects: 57
Study 38564264 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepalliation program
Number of subjects: 0
Study 38564264 — intervention group
Group type: COMPARATOR
Intervention: Traditional standard of care program for palliative care
Number of subjects: 0
Study 38564365 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Dose Isoniazid
Number of subjects: 0
Study 38564365 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38564601 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 19
Study 38564654 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad and Allopurinol combination treatment
Number of subjects: 0
Study 38564654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38564654 — intervention group
Group type: COMPARATOR
Intervention: Active control (Allopurinol alone)
Number of subjects: 0
Study 38564684 — intervention group
Group type: EXPERIMENTAL
Intervention: MTB recommendations from the original review (not disclosed)
Number of subjects: 306
Study 38564684 — intervention group
Group type: COMPARATOR
Intervention: Different MTB review groups
Number of subjects: 306
Study 38564692 — intervention group
Group type: EXPERIMENTAL
Intervention: Active trial follow-up up to 1 year, linkage to the National Death Index (NDI), and obituary searches
Number of subjects: 1169
Study 38564692 — intervention group
Group type: EXPERIMENTAL
Intervention: Linkage to the National Death Index (NDI)
Number of subjects: 1169
Study 38564692 — intervention group
Group type: EXPERIMENTAL
Intervention: Obituary searches
Number of subjects: 1169
Study 38564700 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC group (mFOLFOX6 or CAPOX)
Number of subjects: 744
Study 38564700 — intervention group
Group type: COMPARATOR
Intervention: Upfront surgery group
Number of subjects: 744
Study 38564986 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib monotherapy
Number of subjects: 0
Study 38564986 — intervention group
Group type: COMPARATOR
Intervention: Conventional care regimens (CCR)
Number of subjects: 0
Study 38564986 — intervention group
Group type: EXPERIMENTAL
Intervention: Enasidenib
Number of subjects: 0
Study 38564986 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH2-R140 variant
Number of subjects: 0
Study 38564986 — intervention group
Group type: EXPERIMENTAL
Intervention: IDH2-R172 variant
Number of subjects: 0
Study 38564986 — intervention group
Group type: EXPERIMENTAL
Intervention: RAS and RTK pathway mutations
Number of subjects: 0
Study 38565086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (25 μg every 2 h until Bishop score ≥7, labor, or maximum of 8 doses)
Number of subjects: 104
Study 38565389 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 218
Study 38565389 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 218
Study 38565464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebola vaccine trial participation
Number of subjects: 70
Study 38565464 — intervention group
Group type: EXPERIMENTAL
Intervention: Information sharing and communication strategies
Number of subjects: 70
Study 38565464 — intervention group
Group type: EXPERIMENTAL
Intervention: Community involvement in addressing misconceptions
Number of subjects: 70
Study 38565493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with appendicitis
Number of subjects: 53
Study 38565493 — intervention group
Group type: COMPARATOR
Intervention: Patients without appendicitis
Number of subjects: 53
Study 38565493 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated appendicitis
Number of subjects: 53
Study 38565493 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated appendicitis
Number of subjects: 53
Study 38565753 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of silicone oil after 3-4 months (Group A)
Number of subjects: 64
Study 38565753 — intervention group
Group type: EXPERIMENTAL
Intervention: Late removal of silicone oil after 6-8 months (Group B)
Number of subjects: 64
Study 38565810 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized matching based on therapist effectiveness strengths
Number of subjects: 206
Study 38565810 — intervention group
Group type: COMPARATOR
Intervention: Usual case assignment (control)
Number of subjects: 206
Study 38565810 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-level covariates (higher average severity levels, higher proportion of substance misuse or violence problems)
Number of subjects: 206